Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis

Oh, SuA; Kim, Eun Young

doi:10.1007/s10238-023-01041-0

Cited by 4 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proteasome inhibitor Bortezomib, approved by the FDA for clinical use in multiple myeloma and in AML clinical trials [91,92], has been shown to inhibit NF-kB activation [93]. About 40% of AML patients exhibit increased activity of the NF-kB signaling pathway, and it is constitutively active in CD34+/CD38-blasts from M1, M2, M4, and M5 AML patients [94,95].…”

Section: An Inhibitor Of Nf-kb Activation Bortezomib Downregulates Yy...mentioning

confidence: 99%

YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells

Noguera

Travaglini

Scalea

et al. 2023

Cancers

View full text Add to dashboard Cite

In this study we analyzed the expression of Yin and Yang 1 protein (YY1), a member of the noncanonical PcG complexes, in AML patient samples and AML cell lines and the effect of YY1 downregulation on the AML differentiation block. Our results show that YY1 is significantly overexpressed in AML patient samples and AML cell lines and that YY1 knockdown relieves the differentiation block. YY1 downregulation in two AML cell lines (HL-60 and OCI-AML3) and one AML patient sample restored the expression of members of the CEBP protein family, increased the expression of extrinsic growth factors/receptors and surface antigenic markers, induced morphological cell characteristics typical of myeloid differentiation, and sensitized cells to retinoic acid treatment and to apoptosis. Overall, our data show that YY1 is not a secondary regulator of myeloid differentiation but that, if overexpressed, it can play a predominant role in myeloid differentiation block.

show abstract

Section: An Inhibitor Of Nf-kb Activation Bortezomib Downregulates Yy...mentioning

confidence: 99%

YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells

Noguera

Travaglini

Scalea

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

Li,

Suh,

Lachaine

et al. 2023

Value in Health

View full text Add to dashboard Cite

The Nurse Practitioner Role in Complex Malignant Hematology: A Qualitative Descriptive Study

Forbes,

Carter,

MacKenzie

et al. 2024

Seminars in Oncology Nursing

View full text Add to dashboard Cite

Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis

Cited by 4 publications

References 56 publications

YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells

YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells

Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

The Nurse Practitioner Role in Complex Malignant Hematology: A Qualitative Descriptive Study

Contact Info

Product

Resources

About